Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 1 to 25 of 2564

TitleReference numberPublishedLast updated
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentTA1164
Intrapartum careNG235
Postnatal careNG194
Nusinersen and risdiplam for treating spinal muscular atrophyTA1162
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)TA1163
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatmentTA1159
Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinomaTA1160
Sotatercept for treating pulmonary arterial hypertensionTA1161
Multiple sclerosis in adults: managementNG220
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancerTA1158
Givinostat for treating Duchenne muscular dystrophy in people 6 years and overTA1157
Anaphylaxis: assessment and referral after emergency treatmentNG258
Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapyTA1156
Rozanolixizumab for treating antibody-positive generalised myasthenia gravisTA1155
UK Achondroplasia Network's consensus guideline for multidisciplinary care of children and young people with achondroplasia: NICE reviewNR3
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessmentHTG779
Neonatal infection: antibiotics for prevention and treatmentNG195
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesityTA1152
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatmentTA1153
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)TA1154
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancerTA1150
Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal)TA1151
Digital technologies to support self-management of asthma: early-use assessmentHTG778
Digital technologies for managing non-specific low back pain: early value assessmentHTG712
Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myelomaTA1149

Results per page

  1. 10
  2. 25
  3. 50
  4. All